David Asher
Sports Medicine · Anaheim, CANPI 1275578304
Payments from drug & device makers
Across 357 payments — averaging $20.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- USWM, LLC$1K
- AstraZeneca$730
- Lilly USA, LLC$697
- AbbVie$691
- Pfizer$588
- Alkermes, Inc.$437
- plus $3K from 24 others
What the payments were for
- Travel & lodging$20%
- Food & beverage$6,94693%
- Education$240%
- Gifts$5067%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| USWM, LLC | 39 | $1,099 |
| AstraZeneca | 25 | $730 |
| Lilly USA, LLC | 32 | $697 |
| AbbVie(2 entities) | 37 | $691 |
| Pfizer | 46 | $588 |
| Alkermes, Inc. | 20 | $437 |
| Otsuka America Pharmaceutical, Inc. | 20 | $360 |
| Boehringer Ingelheim | 12 | $355 |
| Johnson & Johnson | 13 | $355 |
| Eisai Inc. | 14 | $309 |
| MDD US Operations, LLC | 24 | $297 |
| Braeburn Inc. | 3 | $264 |
| Indivior Inc. | 8 | $222 |
| Merck | 17 | $213 |
| Novo Nordisk | 7 | $211 |
| Almatica Pharma LLC | 7 | $117 |
| Orexo US, Inc. | 6 | $97 |
| Gilead | 5 | $80 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $63 |
| Kaleo, Inc. | 3 | $57 |
| Teva Pharmaceuticals USA, Inc. | 3 | $47 |
| Sanofi-aventis U.S. LLC | 3 | $36 |
| Neuronetics, Inc. | 1 | $33 |
| Sanofi Pasteur Inc. | 2 | $26 |
| Exact Sciences | 1 | $18 |
| Organon | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Titan Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,478 in reported general payments places this provider in the 65th percentile of 662 sports medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 32 | $6,129 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 21 | $826 |
| Testosterone Cypionate | 13 | $503 |
| Naltrexone Hcl | 13 | $409 |
| Bupropion XlBupropion Hcl | 17 | $380 |
| Buspirone Hcl | 30 | $348 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $244 |
| Ibuprofen | 19 | $201 |
| Pregabalin | 11 | $200 |
| Losartan Potassium | 23 | $171 |
| Atorvastatin Calcium | 22 | $167 |
| Quetiapine Fumarate | 15 | $155 |
| Metformin Hcl | 11 | $118 |
| Amlodipine Besylate | 39 | $102 |
| Gabapentin | 16 | $80 |
Paid to pharmacies, not to this prescriber.
Other sports medicine in Anaheim
- Neal ElattracheLos Angeles$51M
- Nathaniel CohenLos Gatos$6.4M
- Thomas KnappSanta Monica$2.5M
- Seth ShermanStanford$1.8M
- Michael FreehillStanford$1.7M
- Deryk JonesSan Carlos$1.6M
- Allan MishraMenlo Park$1.5M
- Heinz Hoeneckela Jolla$1.4M
- Marc SafranPalo Alto$1.2M
- Stephan YacoubianBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.